Phibro Animal Health (NASDAQ:PAHC) Stock Price Down 4.3% – What’s Next?

Phibro Animal Health Corporation (NASDAQ:PAHC)’s share price was down 4.3% on Thursday . The company traded as low as $38.26 and last traded at $38.2050. 37,577 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 296,314 shares. The stock had previously closed at $39.92.

Wall Street Analysts Forecast Growth

PAHC has been the subject of several recent research reports. Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Citigroup dropped their price target on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Finally, Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $47.67.

Phibro Animal Health Stock Performance

The company’s 50 day moving average price is $34.88 and its 200-day moving average price is $41.83. The stock has a market cap of $1.55 billion, a P/E ratio of 15.68, a price-to-earnings-growth ratio of 1.11 and a beta of 0.46. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.27 and a current ratio of 2.96.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, August 26th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.14. Phibro Animal Health had a net margin of 6.57% and a return on equity of 37.86%. The company had revenue of $396.75 million for the quarter, compared to analyst estimates of $381.18 million. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. Equities analysts forecast that Phibro Animal Health Corporation will post 3.51 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Wednesday, September 2nd will be paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date is Wednesday, September 2nd. Phibro Animal Health’s payout ratio is presently 19.67%.

Institutional Trading of Phibro Animal Health

Hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System boosted its holdings in shares of Phibro Animal Health by 3,861.7% in the 2nd quarter. California State Teachers Retirement System now owns 891,980 shares of the company’s stock worth $28,407,000 after buying an additional 869,465 shares during the last quarter. Millennium Management LLC grew its position in Phibro Animal Health by 4,227.1% during the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after buying an additional 626,492 shares during the period. Ranger Investment Management L.P. purchased a new stake in Phibro Animal Health during the second quarter worth about $9,182,000. Globeflex Capital L P bought a new stake in Phibro Animal Health in the second quarter worth about $5,942,000. Finally, Allspring Global Investments Holdings LLC raised its position in Phibro Animal Health by 145.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 286,172 shares of the company’s stock worth $15,671,000 after acquiring an additional 169,628 shares during the period. 99.34% of the stock is currently owned by institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.